公开(公告)号：IL236131D0

公开(公告)日：2015-02-01

申请号：IL23613114

申请日：2014-12-08

Applicant: ASTRAZENECA AB ,  BOHLIN MARTIN HANS ,  STEWART CRAIG ROBERT

IPC: C07D20060101

Abstract: A process for the preparation of a camsylate salt ((1S)-(+)-10 camphorsulfonic acid) of (1r,1'R,4R)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine is disclosed as well as pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating A²-related pathologies such as Alzheimer's Disease, Down's Syndrome, ²-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's Disease, progressive supranuclear palsy or cortical basal degeneration.

公开(公告)号：WO2013008002A1

公开(公告)日：2013-01-17

申请号：PCT/GB2012/051620

申请日：2012-07-10

Applicant: ASTRAZENECA AB ,  ASTRAZENECA UK LIMITED ,  CONNOLLY, Stephen ,  EBDEN, Mark, Richard ,  LANGER, Thomas ,  STEVEN, Alan, Robert ,  STEWART, Craig, Robert ,  TOMLIN, Paula, Margaret ,  WALTERS, Iain, Alastair, Stewart ,  WILLIAMS, Andrew, John

Inventor： CONNOLLY, Stephen ,  EBDEN, Mark, Richard ,  LANGER, Thomas ,  STEVEN, Alan, Robert ,  STEWART, Craig, Robert ,  TOMLIN, Paula, Margaret ,  WALTERS, Iain, Alastair, Stewart ,  WILLIAMS, Andrew, John

IPC: C07D403/12 ,  C07D205/04 ,  A61K31/506 ,  C07D317/20 ,  C07D317/24 ,  C07C69/92

CPC classification number: C07D403/12 ,  A61K31/506 ,  C07C65/21 ,  C07C69/78 ,  C07C69/92 ,  C07D205/04 ,  C07D239/56 ,  C07D307/12 ,  C07D317/18 ,  C07D317/20 ,  C07D317/24 ,  C07D317/26

Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Abstract translation: 提供了化合物，其为（a）式（I）或（b）的嘧啶磺酰胺或其药学上可接受的盐，化合物的结晶形式，获得化合物的方法，用于制备化合物的药物中间体， 和含有该化合物的药物组合物。 该化合物可用于治疗调节趋化因子受体活性有益的疾病/病症。